查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1887994

人体生物检体市场－全球及区域分析：依样本类型、应用程式、采购类型、最终使用者和地区划分－分析与预测（2025-2035）

Human Biospecimen Market - A Global and Regional Analysis: Focus on Specimen Type, Application, Procurement Type, End User, and Regional Analysis - Analysis and Forecast, 2025-2035
出版日期: | 出版商: BIS Research | 英文 167 Pages | 商品交期: 1-5个工作天内

价格

人体生物检体是指从人体收集的用于科学或临床研究的生物材料，例如组织、血液、体液和分子衍生物。

它们保留了真实的疾病特征，对于研究分子路径、检验诊断方法和开发标靶治疗至关重要。透过标准化的采集、处理和储存，生物检体能够保持完整性并与临床数据关联，从而支持精准的转化研究，并推动精准医学的进步。

关键市场统计数据
预测期 2025-2035
2025 年评估 35.533亿美元
2035 年预测 81.789亿美元
复合年增长率 8.69%

市场概览

全球人类生物样本市场预计将迎来显着成长，到2035年将达到81.789亿美元。推动这一增长的主要因素是全球癌症、罕见疾病、感染疾病和慢性病负担日益加重，这些疾病都需要基于基因组学和精准医学的研究。人类生物检体，包括组织、血浆/血清、週边血单核细胞（PBMC）、原代细胞、DNA、RNA、外泌体和其他分子衍生物，目前是药物发现、生物标记开发、下一代诊断和转化医学的关键投入。

市场扩张的驱动力在于市场对高品质、临床註释、多体学学生物样本的需求成长，以及预分析标准化、自动化生物样本库和数位化样本追踪平台的进步。领先供应商获得 ISO 20387 和 CAP ISO 15189 认证，以及人工智慧驱动的生物样本资料平台的推出等关键进展，反映出监管系统日益成熟，以及客户对可追溯性、知情同意和可重复性的期望不断提高。

另一个主要驱动因素是对国家生物样本库和人群基因组学计画（例如英国生物样本库和美国的「我们所有人」研究计画）的投资不断增长，这些计画共同管理着数百万个生物样本，并实现了大规模的泛组学整合。随着製药和生物技术公司在肿瘤学、免疫学、代谢性疾病和罕见遗传疾病领域拓展其研发管线，这进一步加速了对特征明确的患者样本的需求，这些样本对于靶点检验、伴随诊断和核准后监测至关重要。

儘管北美和欧洲目前凭藉成熟的生物银行网路和雄厚的研究经费在生物样本精准医疗领域处于领先地位，但亚太地区正迅速崛起为高成长区域。中国将占据最大份额，而印度预计将凭藉其不断扩展的临床研究生态系统和大规模的患者群体实现最快成长。同时，拉丁美洲和中东市场也日益关註生物样本相关的精准医疗倡议，从而创造了新的商业机会。

儘管已取得显着进展，但仍面临诸多挑战，包括分析前变异性、高成本的低温储存基础设施、跨境资料传输障碍以及资源匮乏地区高品质样本取得困难等。然而，产业界、学术界和政府机构之间日益密切的合作正逐步克服这些挑战，从而建立规模更大、种类更丰富、管理更符合伦理规范的检体网络。

BioIVT、Crown Bioscience、Precision Medicine Group、Boca Biolistics、ABS Bio 和 Reprocell 等主要企业正透过扩大全球采购、人工智慧驱动的临床数据整合以及疾病特异性队列的开发来增强其竞争优势。随着精准医疗、多组体学研究和先进治疗方法的加速发展，人类生物检体市场已成为未来生物医学创新的核心驱动力，促进临床应用并改善全球患者的治疗效果。

对产业的影响

人类生物检体产业正成为精准医疗的重要基石，它能够提供高品质、具有临床意义的生物材料，用于生物标记发现、临床试验招募和诊断方法开发。随着癌症、代谢失调、中枢神经系统疾病和罕见疾病等疾病成为全球研发的驱动力，製药、生物技术和诊断领域对高註释组织、相应生物体液和活性原代细胞的需求呈指数级增长。

像 Crown Bioscience、BioIVT LLC、Precision Medicine Group, LLC 和 Grifols, SA 这样的知名供应商正在通过提供具有强大监管链的多基质、纵向、基因组学生物样本来重新构想研究工作流程，从而减少实验变异性，简化检测检验，并加速药物开发决策，尤其是在肿瘤学领域，超过 55% 的临床标誌是由生物开发的决策，尤其是在肿瘤学领域由 55% 的临床开发领域由生物主导。

市场也在推动样本采集、处理和记录方法的改进，越来越多的公司开始遵循正式的品质和监管标准，例如 CAP ISO 15189 和 ISO 20387。这确保了生物样本来源符合伦理规范，品质优良，并适用于诊断、临床研究和先进疗法。商业生物样本库、学术医疗中心和政府资助的人群基因组学计画之间的策略合作，正在扩大获取不同患者群体（包括高价值的肿瘤和罕见疾病样本）的机会。这些伙伴关係加强了全球生物检体管道，减少了获取瓶颈，并支持去中心化的细胞和基因治疗 (CGT) 及转化研究生态系统。

总体而言，人类生物检体市场正在改变生命科学工具的格局，将可靠且数据丰富的样本定位为治疗成功的核心决定因素。透过与受监管的工作流程和高影响力发现平台的深度整合，该行业正在直接提高临床开发效率，推动个人化医疗策略，并加速将科学创新转化为切实的患者获益。

市场区隔:

类别 1：依样本类型

  • 组织检体
  • 生物体液
  • 细胞材料
  • 核酸
  • 其他的

以样本类型划分，组织检体仍将是全球人类生物样本市场的主要细分市场，预计2024年将占据41.30%的市场。从2025年到2035年，受其在癌症研究、精准医疗、数位病理学和空间体学等领域的关键作用推动，组织样本预计将以7.48%的复合年增长率增长。高价值的FFPE组织块、冷冻组织和切除标本将继续支持生物标记发现、伴随诊断开发和肿瘤-正常组织测序分析，使组织成为最具盈利的类别。受液态生物检体活检、基于ctDNA的诊断和免疫肿瘤学计画发展推动，血浆、血清、週边血单核细胞（PBMC）和尿液等生物体液的复合年增长率更高。人们对微创采样和长期患者监测的日益青睐预计将进一步增强生物体液生物检体对市场成长的贡献。

细分 2：按应用

  • 生物医学研究
  • 诊断
  • 治疗研发
  • 临床试验

按应用领域划分，生物医学研究领域在2024年引领全球人类生物样本市场，占45.00%的市场。这一主导地位得益于药物发现研究、转化医学计画和生物标记开发中对高品质组织、生物体液和原代细胞的持续需求。基因组学、蛋白质组学、代谢体学和空间生物学等多体学平台的日益普及，进一步巩固了生物医学研究作为带註释生物样本主要消费领域的地位。

随着液态生物检体检测、伴随诊断驱动的药物核准以及全球监管检测检验的兴起，诊断和临床开发应用正在迅速扩展。生物製药公司依赖特征明确的人体样本进行患者分层、分析性能评估和真实世界证据生成。随着精准医疗的加速普及，生物样本在诊断、免疫肿瘤学、神经病学和罕见疾病研究中的应用预计将在2035年之前推动强劲成长，并提高该领域对整体市场收入的贡献。

细分3：依采购类型

  • 预收款项（按需收）
  • 回顾性检体

按采集类型划分，到2024年，全球人类生物检体市场将以回顾性样本为主导，占据55.00%的市场份额。这得归功于现有的庞大样本库，例如FFPE组织块、冷冻组织、血浆/血清、週边血单核细胞（PBMC）以及其他保存在医院生物样本库和国家研究网络中的生物体液。这些样本具有获取迅速、批量通量高以及涵盖多种疾病群体（包括肿瘤、代谢性疾病和感染疾病）等优势，使其成为药物发现研究、转化研究和早期诊断开发的重要来源。

同时，前瞻性（按需）样本采集虽然目前占比不高，却是成长最快的领域。其成长主要受精准监测需求的驱动，包括严格的纳入和排除标准、基因谱分析、新鲜组织采集、罕见儿童疾病的样本采集以及与真实世界临床数据关联的纵向样本采集。随着生物标记驱动的临床试验、多组体学研究以及精准医疗研发管线的扩展，预计到2035年，前瞻性样本采集的贡献将显着增长。

细分 4：按最终用户

  • 製药和生物技术公司
  • 合约研究组织（CRO）
  • 学术研究机构
  • 医院和生物样本库
  • 诊断实验室
  • 政府和非营利组织

从终端用户来看，到2024年，全球人类生物检体市场将由製药和生技公司主导，占48.00%的市场。这些公司是药物研发生命週期中，对註释完善的人体组织、生物体液和细胞材料需求量最大、最稳定的使用者。它们推动了对高品质疾病特异性队列、多基质相容样本以及符合监管要求的生物样本的检验，以支持目标发现、转化研究、生物标记验证、伴随诊断开发和临床进展。

细分5：按地区

  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 其他的
  • 亚太地区
    • 日本
    • 印度
    • 中国
    • 澳洲
    • 韩国
    • 其他的
  • 其他地区

亚太地区的人类生物检体市场正在扩张。中国占大规模的人口规模、较高的癌症和代谢性疾病负担、对生物样本库基础设施的大力投资，以及精准医疗和多组体学计画的快速发展。印度是成长最快的市场，这主要得益于临床试验活动的增加、手术和病理样本获取量的提高，以及不断完善的数位医疗基础设施，从而能够从不同的患者群体中大规模获取样本。

日本和韩国透过先进的国家生物样本库网路和基因组研究倡议，提供高品质、註释详尽的生物样本。澳洲拥有强大的转化研究能力和广泛的临床实践，而新加坡和马来西亚则作为数据互联的物流枢纽，支持全球生物样本交换。印尼、越南和菲律宾等东南亚市场正在逐步扩张，但仍受到基础设施、监管差异和低温运输限制等因素的限制。

亚太地区幅员辽阔，疾病种类繁多，种族构成复杂，因此成为全球生物检体的重要来源地，以支持肿瘤学、代谢性疾病、神经病学和罕见病研究。

人类生物检体市场的最新趋势

  • 2025 年 10 月，BioIVT 收购了总部位于西班牙的 BeCytes Biotechnologies，以加强其在欧洲的生物银行规模，并扩大获得符合伦理的人类生物检体的途径，以支持新型方法调查方法(NAM)。
  • 2025 年 2 月，Crown Bioscience 与 Indivimed Services 合併，将两家公司的生物样本和多体学平台结合起来，透过整合人类生物样本解决方案来加强肿瘤药物发现研究。
  • 2025 年 6 月，iProcess Global Research 与 ViewsML 合作，整合 AI 驱动的虚拟 IHC 生物标记测试，以增强基于生物样本的数位病理学和组织存檔生物标记分析，用于研究和诊断。
  • 2025 年 9 月，ABS Bio 的生物样本采购和生物银行营运获得了 ISO 20387 认证，进一步巩固了其对高品质、符合伦理的人类生物样本和全球生物库标准的承诺。
  • 2025 年 8 月，Logical Biological 与 Bcell Design 合作开发了模拟天然人体生物检体样本的疾病状态血浆材料，为诊断和研究应用提供了一种永续的高性能替代方案。
  • 2025 年 1 月，Reprocell 推出了 ReproRegistry，这是一个志愿者登记系统，旨在将拥有健康或患病皮肤的个人联繫起来，用于研究目的，从而获取用于皮肤病学和药物发现的人类皮肤样本。
  • 2024 年 9 月，Discovery Life Sciences 整合了 Lunaphor 的 COMET 平台，以扩展其用于临床生物样本分析的多重空间生物学能力。

需求——驱动因素、挑战与机会

市场需求驱动因素：附註的人类生物检体日益普及

精准医疗的兴起显着提升了对高品质、经临床註释的人类生物检体的需求，这些样本能够准确反映真实世界的疾病生物学特征。如今，製药和生物技术公司依靠肿瘤-正常组织对照样本、ctDNA匹配的血浆、定序级核酸以及疾病特异性免疫细胞亚群，来实现生物标记主导的药物发现和开发、分层临床试验入组以及伴随诊断检验。肿瘤学领域正处于这一变革的前沿，生物标记指导的临床试验比例已从2000年的约15%增长到如今的55%以上，目前已有超过60种获得FDA核准的疗法与检验诊断检测相结合。

在肿瘤学领域之外，罕见疾病研究也推动了对特征明确、可直接用于患者的生物样本的需求，包括初代细胞、纤维母细胞、神经肌肉组织、儿童组织以及来自小规模、​​基因明确的队列的血液样本。全国基因组检测项目，例如英国国家医疗服务体系（NHS）的ctDNA癌症筛检计画（预计每年将惠及约15,000名患者），凸显了精准医疗与稳健的生物样本供应链之间日益紧密的联繫。这些进展需要严格的预分析处理、纵向临床註释以及可靠的可追溯性框架，以确保多体学应用中资料品质的一致性。

随着製药企业将标靶治疗项目列为优先事项并减少后期临床试验失败率，获取临床上丰富的标准化生物样本已成为一项战略要务。预计这种依赖性将持续增长，带有註释的人类生物样本将成为下一代药物发现、转化科学和监管决策的核心驱动力。

市场挑战：分析前变异性与生物检体品质差距

分析前变异性仍然是人类生物检体市场中最主要的阻碍因素之一，因为即使在采集、处理、运输和储存过程中出现微小偏差，也可能导致不可逆的分子劣化。处理时间、试管类型、抗凝血剂、离心参数、冻融循环次数以及储存温度（-20 度C与 -80 度C）的差异都会显着改变 DNA、RNA、蛋白质和代谢物的谱图，直接影响其在新一代定序 (NGS)、蛋白质组学、代谢体学和空间体学中的适用性。诸如 SPIDIA-RNA 等大规模品质评估表明，只有不到一半的参与实验室能够始终满足 RNA 完整性要求，高达 28% 的实验室在多个参数上出现「失控」结果，凸显了整个市场普遍存在的不一致性。

元资料报告不足进一步加剧了这个问题。许多储存的样本缺乏必要的分析前信息，例如处理前的时间、溶血指数或冻融历史，导致它们无法用于符合监管要求的生物标誌物研究或需要高灵敏度和可重复性的多体学学研究。因此，现有生物样本库中相当一部分样本无法支持精准医疗应用，尤其是那些年代久远且记录不全的样本库。

为了保持竞争力，生物样本供应商现在必须实施基于SPREC的文件记录、统一的标准操作规程（SOP）以及贯穿生物样本生命週期的严格即时品质监控。这种标准化趋势增加了营运成本，提高了能力门槛，有利于拥有成熟品管系统的大型供应商，同时限制了小规模、标准化程度较低的供应商进入市场。

市场机会：疾病特异性罕见疾病队列的商业化

目前已知的罕见疾病和超罕见疾病超过10,000种，但核准的治疗方法却寥寥无几。因此，高品质、与疾病相符的生物样本对于支持诊断创新、生物标记发现和治疗方法研发至关重要。许多罕见疾病缺乏成熟的样本库，且患者群体分布分散，严重限制了相关队列的取得。製药公司越来越需要特殊的生物样本，例如纤维母细胞、神经肌肉组织、神经肌肉组织、脑脊髓液样本以及相应的时序样本，以表征疾病进展并检验基因靶点，尤其是在代谢性疾病、儿童疾病和遗传性疾病领域。

监管政策的发展进一步推动了这项机会。虽然孤儿药认定和加速核准流程的兴起提高了研发对罕见疾病适应症的关注度，但可靠生物样本的短缺仍然是一大瓶颈。诸如美国国立卫生研究院罕见疾病治疗加速器计画等国家级倡议，凸显了对能够将生物学变化与临床结果联繫起来的多时间点数据集和註释完善的样本的需求。

这为能够建立疾病特异性登记库、实施精准招募策略并创建包含表型特征、基因组数据和追踪时间线等资讯且已获得受试者同意的、数据丰富的资料库的专业生物样本供应商创造了巨大的商业机会。随着罕见疾病研发管线的不断扩展，提供此类高价值材料的能力将成为关键的商业性，而具备相应能力的供应商将把自己定位为加速为服务不足的患者群体开发精准药物的重要合作伙伴。

市场趋势：产品发布和监管核准不断增加

在产品创新和监管进步的推动下，人类生物检体市场正从传统的交易型样本供应模式转型为高价值、合规驱动的结构化生态系统。供应商正在加速推出各类专业产品，包括针对特定适应症的组织样本、多基质生物生物检体盒、针对特定疾病的外周血单核细胞 (PBMC)、符合 GMP 标准的细胞材料，以及由供体主导的登记系统，例如专注于皮肤病学的 ReproRegistry。数位化也在快速发展，人工智慧驱动的数据平台整合了生物检体元资料、临床结果和基因组图谱，从而提升了可追溯性、样本选择和研究相关性。

同时，标准化的分析前流程、检验的工作流程和受监管的生物样本库作业正在转变，越来越多的供应商获得了 CAP ISO 15189 (2022) 和 ISO 20387 等认证。这种发展使得生物样本能够支援受监管的工作流程，例如诊断检验、伴随诊断配对和临床试验执行，从而推动了製药、生物技术和体外诊断开发人员的需求。

然而，这项变化也提高了竞争门槛。高品质的文件、完整的监管炼和合规基础设施如今已成为基本要求，而非增值差异化因素。拥有完善品质管治系统的大型营运商和专业平台将从中受益最多，而缺乏监管成熟度的传统供应商则可能被限制在利润率低、同质化的市场细分领域。

主要市场参与企业及竞争摘要

入选公司名单是根据初步研究结果、产品组合的全面性、监管认证和全球生物样本采购能力来选择的。

Crown Bioscience、Grifols SA、BioIVT LLC 和 Precision Medicine Group, LLC 等成熟供应商拥有强大的市场地位，其生物样本库规模大规模且来源符合伦理规范，并拥有 CAP/ISO 认证的生物银行营运体系，以及与製药、生物技术和诊断公司建立的长期伙伴关係。它们不断扩展的多体学学样本库和丰富的数据资源为先进的转化医学和精准医学研究提供了支持。

同时，像 Logical Biological 和 Labtoo 这样的新兴企业正在透过灵活的采购模式、疾病特异性样本解决方案和数位化采购平台来扩大其业务范围（尤其是在欧洲和亚太地区），从而简化研究人员在全球范围内获取生物样本的途径。

这些公司携手合作，正在加强全球生物检体供应链，增加样本多样性，推动提高可追溯性和监管合规性，并引领市场走向高品质、临床註释的资源，以支持药物发现和诊断开发。

该市场的一些主要企业包括：

  • BioIVT LLC.
  • Crown Bioscience
  • Precision Medicine Group, LLC
  • Grifols, SA

目录

执行摘要

第一章 全球人类生物检体市场：产业展望

  • 市场概览
  • 市场趋势
  • 供应链概览
  • 监管状态
  • 市场动态

2. 全球人类生物检体市场（依样本类型划分）

  • 概述
  • 组织标本
  • 生物体液
  • 细胞材料
  • 核酸
  • 其他的

第三章 全球人类生物检体市场（依应用划分）

  • 概述
    • 生物医学研究
    • 诊断
    • 治疗研发
    • 临床试验

4. 全球人类生物检体市场（依采购类型划分）

  • 概述
    • 专业特定係列（按需系列）
    • 回顾性样本

5. 全球人类生物检体市场（依最终用户划分）

  • 概述
    • 製药和生物技术公司
    • CRO
    • 学术研究机构
    • 医院和生物样本库
    • 诊断检查室
    • 政府和非营利组织

第六章 区域

  • 区域摘要
  • 北美洲
    • 区域概览
    • 市场成长驱动因素
    • 影响市场的因素
    • 市场规模及预测
    • 美国
    • 加拿大
  • 欧洲
    • 区域概览
    • 市场成长驱动因素
    • 成长抑制因素
    • 市场规模及预测
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 其他的
  • 亚太地区
    • 区域概览
    • 市场成长驱动因素
    • 成长抑制因素
    • 市场规模及预测
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
    • 其他的
  • 其他地区
    • 区域概览
    • 市场成长驱动因素
    • 成长抑制因素
    • 市场规模及预测

第七章 竞争基准化分析与公司概况

  • 2020-2025年主要策略与发展
  • 2020-2025年关键发展分析（按年份划分）
  • 关键发展分析（依公司划分），2020-2025 年
  • 公司简介
    • BioIVT LLC.
    • Crown Bioscience
    • iProcess Global Research Inc.
    • ABS Bio, Inc.
    • Precision Medicine Group, LLC
    • REPROCELL Inc.
    • LifeNet Health LifeSciences
    • Logical Biological
    • Europa Biosite
    • Discovery Life Sciences
    • Boca Biolistics, LLC
    • ProteoGenex
    • US Biolab Corporation, Inc.
    • Bay Biosciences
    • Grifols, SA

第八章调查方法

Product Code: BHP3398SA

This report can be delivered within 1 working day.

Introduction of Human Biospecimen

Human biospecimens are biological materials such as tissues, blood, biofluids, and molecular derivatives collected from the human body for scientific and clinical investigation. They retain real-world disease characteristics and are essential for studying molecular pathways, validating diagnostics, and developing targeted therapies. With standardized collection, processing, and storage that preserve integrity and link clinical data, biospecimens enable accurate translational research and drive advancements in precision medicine.

KEY MARKET STATISTICS
Forecast Period2025 - 2035
2025 Evaluation$3,553.3 Million
2035 Forecast$8,178.9 Million
CAGR8.69%

Market Introduction

The global human biospecimen market is expected to witness significant growth, projected to reach $8,178.9 million by 2035, supported by the rising global burden of cancer, rare diseases, infectious diseases, and chronic conditions that require genomic and precision-based research. Human biospecimens, including tissues, plasma/serum, PBMCs, primary cells, and molecular derivatives such as DNA, RNA, and exosomes, now serve as mission-critical inputs for drug discovery, biomarker development, next-generation diagnostics, and translational medicine.

Market expansion has been driven by the shift toward high-quality, clinically annotated, and multi-omic-ready biospecimens, alongside advancements in pre-analytical standardization, biorepository automation, and digital sample-tracking platforms. Key developments such as ISO 20387 and CAP ISO 15189 accreditations across leading providers, and the launch of AI-enabled biospecimen data platforms, reflect increasing regulatory maturity and rising customer expectations for traceability, consent compliance, and reproducibility.

Strong momentum also stems from growing investments in national biobanks and population-genomics programs, including the U.K. Biobank and the U.S. All of Us Research Program, which collectively manage millions of biospecimens and enable pan-omics integration at scale. Pharmaceutical and biotechnology companies further accelerate demand as they expand pipelines in oncology, immunology, metabolic diseases, and rare genetic disorders, where deeply characterized patient samples are essential for target validation, companion diagnostics, and post-approval monitoring.

While North America and Europe currently lead in adoption due to mature biobanking networks and robust research funding, Asia-Pacific is rapidly emerging as a high-growth region with China holding the largest share and India projected to grow the fastest, driven by expanding clinical research ecosystems and access to large patient populations. Meanwhile, Latin America and the Middle East markets are increasingly focusing on biospecimen-linked precision-medicine initiatives, presenting new commercialization opportunities.

Despite strong progress, challenges persist, including pre-analytical variability, high-cost cryogenic infrastructure, cross-border data-transfer barriers, and limited access to high-quality samples in lower-resource settings. However, increased collaboration among industry, academia, and government bodies is steadily overcoming these gaps and enabling larger, more diverse, and ethically governed specimen networks.

Leading companies such as BioIVT, LLC, Crown Bioscience, Precision Medicine Group, LLC, Boca Biolistics, ABS Bio, and Reprocell are strengthening competitive positioning through global sourcing expansion, AI-powered clinical-data integration, and disease-specific cohort development. As precision medicine, multi-omics research, and advanced therapies accelerate, the human biospecimen market is positioned as a core enabler of future biomedical innovation, unlocking faster clinical translation and improved patient outcomes worldwide.

Industrial Impact

The human biospecimen industry is becoming an essential backbone of precision medicine by enabling access to high-quality, clinically contextualized biological materials needed for biomarker discovery, clinical trial enrollment, and diagnostic development. With cancer, metabolic disorders, CNS diseases, and rare diseases driving global R&D, demand for deeply annotated tissues, matched biofluids, and viable primary cells is rising sharply across pharmaceutical, biotech, and diagnostic segments.

Established providers such as Crown Bioscience, BioIVT LLC, Precision Medicine Group, LLC, and Grifols, S.A. are reshaping research workflows by delivering multi-matrix, longitudinal, and genomics-ready biospecimens with robust chain-of-custody documentation. These offerings reduce experimental variability, streamline assay validation, and accelerate drug development decision-making, particularly in oncology, where >55% of clinical trials are now biomarker-guided.

The market is also driving improvements in how samples are collected, processed, and documented, with more companies following formal quality and regulatory standards such as CAP ISO 15189 and ISO 20387. This ensures that biospecimens are ethically sourced, high-quality, and suitable for use in diagnostics, clinical research, and advanced therapies. Strategic collaborations between commercial biobanks, academic medical centers, and government-funded population-genomics programs are expanding access to diverse patient cohorts, including high-value oncology and rare-disease samples. These partnerships strengthen global biospecimen pipelines, reduce access bottlenecks, and support decentralized CGT and translational-research ecosystems.

Overall, the human biospecimen market has been transforming the life-science tools landscape, making reliable, data-rich human samples a core determinant of therapeutic success. By deepening integration with regulated workflows and high-impact discovery platforms, the industry is directly improving clinical-development efficiency, advancing personalized-medicine strategies, and accelerating the translation of scientific innovation into real-world patient benefit.

Market Segmentation:

Segmentation 1: By Specimen Type

  • Tissue Specimens
  • Biofluids
  • Cellular Material
  • Nucleic Acids
  • Others

Tissue specimens remain the leading segment by specimen type in the global human biospecimen market, holding 41.30% market share in 2024, with a projected CAGR of 7.48% during 2025-2035, driven by their essential role in oncology research, precision medicine, and the growth of digital pathology and spatial omics. High-value FFPE blocks, fresh-frozen tissues, and resection specimens continue to support biomarker discovery, companion diagnostics development, and tumor-normal sequencing, making tissues the highest revenue-generating category. Biofluids, including plasma, serum, PBMCs, and urine, are growing at a higher CAGR, supported by the rise of liquid biopsy testing, ctDNA-based diagnostics, and immuno-oncology programs. The growing preference for minimally invasive sampling and longitudinal patient monitoring is expected to strengthen the future contribution of biofluid-based biospecimens to market growth.

Segmentation 2: By Application

  • Biomedical Research
  • Diagnostics
  • Therapeutic Development
  • Clinical Trials

Based on application, the global human biospecimen market was led by the biomedical research segment, which accounted for 45.00% share in 2024. This dominance has been driven by sustained demand for high-quality tissues, biofluids, and primary cells across discovery biology, translational programs, and biomarker development. The growing adoption of multi-omics platforms, including genomics, proteomics, metabolomics, and spatial biology, further strengthens biomedical research as the primary consumer of annotated biospecimens.

Diagnostics and clinical development applications are expanding rapidly as liquid biopsy testing, CDx-linked drug approvals, and regulated assay validation increase globally. Biopharma sponsors rely on deeply characterized human samples for patient stratification, analytical performance evaluation, and real-world evidence generation. As precision-medicine adoption accelerates, biospecimen utilization in diagnostics, immuno-oncology, neurology, and rare-disease studies is expected to drive strong future growth and enhance this segment's contribution to overall market revenue through 2035.

Segmentation 3: By Procurement Type

  • Prospective Collection (On-Demand Collection)
  • Retrospective Samples

Based on procurement type, the global human biospecimen market was led by retrospective samples, which held a 55.00% share in 2024, supported by vast existing repositories of FFPE blocks, frozen tissues, plasma/serum, PBMCs, and other archived biofluids stored across hospital biobanks and national research networks. These samples offer rapid accessibility, high batch volumes, and coverage across multiple disease cohorts, including oncology, metabolic disorders, and infectious diseases, making them the primary source for discovery biology, translational studies, and early diagnostic development.

Prospective (on-demand) collections command a smaller share today but represent the fastest-growing segment. Their growth has been driven by precision research requirements, including strict inclusion/exclusion criteria, genetic profiling, fresh tissue acquisition, pediatric rare-disease sampling, and longitudinal collections linked with real-world clinical data. As biomarker-guided trials, multi-omics studies, and precision-medicine pipelines scale, the contribution of prospective collections is expected to expand significantly through 2035.

Segmentation 4: By End User

  • Pharmaceutical and Biotechnology Companies
  • Contract Research Organizations (CROs)
  • Academic and Research Institutes
  • Hospitals and Biobanks
  • Diagnostic Laboratories
  • Government and Non-Profit Organizations

Based on end user, the global human biospecimen market was led by pharmaceutical and biotechnology companies, which held a 48.00% share in 2024, as they represent the largest and most consistent consumers of well-annotated human tissues, biofluids, and cellular materials across the drug development life cycle. These organizations drive premium-value demand for disease-specific cohorts, multi-matrix matched samples, and regulatory-ready biospecimens that support target discovery, translational programs, biomarker validation, companion diagnostic development, and clinical progression.

Segmentation 5: By Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest-of-Europe
  • Asia-Pacific
    • Japan
    • India
    • China
    • Australia
    • South Korea
    • Rest-of-Asia-Pacific
  • Rest-of-the-World

The human biospecimen market in the Asia-Pacific region is expanding. China accounts for the highest market share, driven by large population size, high cancer and metabolic disease burden, strong investment in biobank infrastructure, and rapid growth in precision-medicine and multi-omics programs. India is the fastest-growing market, supported by expanding clinical-trial activity, increasing availability of surgical and pathology samples, and improving digital-health infrastructure that enables scalable sourcing from diverse patient cohorts.

Japan and South Korea contribute high-quality, deeply annotated biospecimens through advanced national biobank networks and genomics initiatives. Australia offers strong translational research capabilities and procedure-rich clinical environments, while Singapore and Malaysia serve as data-linked logistics hubs supporting global biospecimen exchange. Southeast Asian markets such as Indonesia, Vietnam, and the Philippines are gradually expanding but remain constrained by infrastructure, regulatory variability, and cold-chain limitations.

Collectively, APAC offers unmatched scale, disease diversity, and multi-ethnic representation, making it a priority region for globally sourced biospecimens supporting oncology, metabolic disorders, neurology, and rare diseases research.

Recent Developments in the Human Biospecimen Market

  • In October 2025, BioIVT acquired Spain-based BeCytes Biotechnologies to strengthen its European biobanking footprint and expand access to ethically sourced human biospecimens supporting new approach methodologies (NAMs).
  • In February 2025, Crown Bioscience merged with Indivumed Services, combining their biospecimen and multi-omics platforms to enhance oncology drug discovery through integrated human biospecimen solutions.
  • In June 2025, iProcess Global Research partnered with ViewsML to integrate AI-powered virtual IHC biomarker testing, enhancing biospecimen-based digital pathology and tissue-sparing biomarker analysis for research and diagnostics.
  • In September 2025, ABS Bio earned ISO 20387 accreditation for its biospecimen procurement and biobanking operations, reinforcing its commitment to high-quality, ethically sourced human biospecimens and global biorepository standards.
  • In August 2025, Logical Biological partnered with Bcell Design to develop engineered disease state plasma materials replicating native human biospecimens, ensuring sustainable and high-performance alternatives for diagnostic and research applications.
  • In January 2025, Reprocell launched ReproRegistry, a volunteer registry connecting individuals with healthy or diseased skin for research, enabling human skin sample procurement for dermatology and drug discovery.
  • In September 2024, Discovery Life Sciences integrated Lunaphore's COMET platform to expand multiplexed spatial biology capabilities for clinical biospecimen analysis.

Demand - Drivers, Challenges, and Opportunities

Market Demand Drivers: Rising Adoption of Annotated Human Biospecimens

The shift toward precision medicine is significantly increasing demand for high-quality, clinically annotated human biospecimens that accurately reflect real-world disease biology. Pharmaceutical and biotechnology companies now depend on tumor-normal matched tissues, ctDNA-ready plasma, sequencing-grade nucleic acids, and disease-specific immune cell subsets to enable biomarker-driven drug development, stratified clinical trial enrollment, and companion diagnostic validation. Oncology has been at the forefront of this transformation, with biomarker-guided trials rising from roughly 15% in 2000 to over 55% today, and more than 60 FDA-approved therapies now linked to a validated CDx assay.

Beyond oncology, rare-disease research has amplified the need for deeply characterized, patient-matched biospecimens, including primary cells, fibroblasts, neuromuscular and pediatric tissues, and blood samples from small, genetically defined cohorts. National genomic-testing programs such as NHS England's ctDNA cancer screening initiative, projected to benefit around 15,000 patients annually, further highlight the growing link between precision healthcare delivery and robust biospecimen supply chains. These advancements require rigorous pre-analytics, longitudinal clinical annotation, and reliable traceability frameworks to ensure consistent data quality across multi-omics applications.

As pharmaceutical sponsors continue to prioritize targeted therapy programs and reduce late-stage clinical failures, access to clinically rich, standardized biospecimens has become a strategic necessity. This reliance is expected to intensify, making annotated human biospecimens a central enabler of next-generation drug discovery, translational science, and regulatory decision-making.

Market Challenges: Pre-Analytical Variability and Biospecimen Quality Gaps

Pre-analytical variability remains one of the most critical restraints in the human biospecimen market because even minor deviations during collection, processing, transport, or storage can cause irreversible molecular degradation. Differences in handling timelines, tube types, anticoagulants, centrifugation parameters, freeze-thaw cycles, and storage temperatures (-20°C vs. -80°C) significantly alter DNA, RNA, protein, and metabolite profiles, directly impacting suitability for NGS, proteomics, metabolomics, and spatial omics. Large-scale quality assessments such as SPIDIA-RNA have demonstrated that fewer than half of participating laboratories consistently meet RNA integrity requirements, and up to 28% show multiple parameters "out of control," highlighting widespread inconsistency across the market.

Compounding this issue is inadequate metadata reporting. Many archived samples lack essential pre-analytical details such as time-to-processing, hemolysis indices, and freeze-thaw history, making them unusable for regulatory-aligned biomarker research or multi-omics studies requiring high sensitivity and reproducibility. As a result, significant portions of legacy biobank inventory, particularly older, poorly documented collections, cannot support precision-medicine applications.

To remain competitive, biospecimen providers must now adopt SPREC-based documentation, harmonized SOPs, and stringent, real-time quality monitoring throughout the biospecimen lifecycle. This push toward standardization increases operational costs and raises capability thresholds, favoring large-scale and quality-mature vendors while limiting participation from small, unstandardized suppliers.

Market Opportunities: Commercialization of Disease-Specific Rare-Disease Cohorts

With more than 10,000 known rare and ultra-rare diseases and very few approved therapies, there is a critical unmet need for high-quality, disease-matched biospecimens to support diagnostic innovation, biomarker discovery, and therapeutic development. Many rare conditions lack established sample repositories, and patient populations are geographically dispersed, making access to relevant cohorts extremely limited. Pharmaceutical sponsors increasingly require specialized biospecimens such as fibroblasts, neuromuscular and pediatric tissues, CSF samples, and matched longitudinal aliquots to characterize disease progression and validate genetic targets, particularly in metabolic, neuromuscular, and inherited disorders.

Regulatory momentum further reinforces this opportunity. Rising orphan-drug designations and accelerated approval pathways have intensified R&D focus on uncommon indications, but the scarcity of reliable biospecimens remains a major bottleneck. National initiatives like the NIH Rare Disease Cures Accelerator highlight the demand for multi-timepoint datasets and deeply annotated samples capable of linking biological changes with clinical outcomes.

This creates a strong commercial opportunity for specialized biospecimen providers that can establish disease-specific registries, deploy targeted recruitment strategies, and build consent-ready, data-rich repositories that include phenotypic profiles, genomic data, and follow-up timelines. As rare-disease pipelines continue expanding, the ability to deliver these high-value materials will become a key differentiator, positioning capable vendors as essential partners in accelerating precision therapy development for the underserved patient population.

Market Trends: Increasing Product Launches and Regulatory Approvals

Product innovation and regulatory alignment are reshaping the human biospecimen market from a transactional sample-supply model into a structured ecosystem of higher-value, compliance-driven offerings. Vendors are accelerating launches of specialty products such as indication-specific tissue panels, multi-matrix biospecimen kits, disease-state PBMCs, GMP-grade cell materials, and donor-driven registries like dermatology-focused ReproRegistry. Digital enablement is also advancing rapidly, with AI-powered data platforms now integrating biospecimen metadata, clinical outcomes, and genomic profiles to improve traceability, sample selection, and research relevance.

Simultaneously, more providers are obtaining accreditations such as CAP ISO 15189:2022 and ISO 20387, signaling a move toward standardized pre-analytics, validated workflows, and regulatory-compatible biorepository operations. This evolution is enabling biospecimens to support regulated workflows, including diagnostic validation, companion-diagnostic alignment, and clinical trial execution, expanding demand across pharma, biotech, and IVD developers.

However, this shift is also raising the competitive bar; high-quality documentation, chain-of-custody integrity, and compliance infrastructure are now baseline requirements rather than value-added differentiators. Scale players and specialized platforms with strong quality governance stand to benefit most, while traditional suppliers without regulatory maturity risk being limited to lower-margin, commoditized market segments.

How can this report add value to an organization?

Product/Innovation Strategy: The report offers in-depth insights into the latest technological advancements in human biospecimens, enabling organizations to drive innovation and develop cutting-edge products tailored to market needs.

Growth/Marketing Strategy: By providing comprehensive market analysis and identifying key growth opportunities, the report equips organizations with the knowledge to craft targeted marketing strategies and expand their market presence effectively.

Competitive Strategy: The report includes a thorough competitive landscape analysis, helping organizations understand their competitors' strengths and weaknesses and allowing them to strategize effectively to gain a competitive edge in the market.

Regulatory and Compliance Strategy: It provides updates on evolving regulatory frameworks, approvals, and industry guidelines, ensuring organizations stay compliant and accelerate market entry for new human biospecimens.

Investment and Business Expansion Strategy: By analyzing market trends, funding patterns, and partnership opportunities, the report assists organizations in making informed investment decisions and identifying potential M&A opportunities for business growth.

Methodology

Key Considerations and Assumptions in Market Engineering and Validation

  • The base year considered for the calculation of the market size is 2024. A historical year analysis has been done for the period FY2023. The market size has been estimated for FY2024 and projected for the period FY2025-FY2035.
  • The scope of this report has been carefully derived from extensive interactions with experts and stakeholders across leading biospecimen companies, clinical research institutions, and biobanking networks worldwide. This report provides a comprehensive market analysis of the human biospecimen ecosystem, covering specimen types, procurement models, end-user demand dynamics, regulatory and ethical frameworks, and emerging technology integrations such as multi-omics data enablement and digitalized biobanking operations.
  • Revenues of the companies have been referenced from their annual reports for FY2023 and FY2024. For private companies, revenues have been estimated based on factors such as inputs obtained from primary research, funding history, market collaborations, and operational history.
  • The market has been mapped based on the available human biospecimen products. All the key companies with significant offerings in this field have been considered and profiled in this report.

Primary Research

The primary sources involve industry experts in human biospecimen, including the market players offering products and services. Resources such as CEOs, vice presidents, marketing directors, and technology and innovation directors have been interviewed to obtain and verify both qualitative and quantitative aspects of this research study.

The key data points taken from the primary sources include:

  • Validation and triangulation of all the numbers and graphs
  • Validation of the report's segmentation and key qualitative findings
  • Understanding the competitive landscape and business model
  • Current and proposed production values of a product by market players
  • Validation of the numbers of the different segments of the market in focus
  • Percentage split of individual markets for regional analysis

Secondary Research

Open Sources

  • Certified publications, articles from recognized authors, white papers, directories, and major databases, among others
  • Annual reports, SEC filings, and investors' presentations of the leading market players
  • Company websites and a detailed study of their product portfolio
  • Gold standard magazines, journals, white papers, press releases, and news articles
  • Paid databases

The key data points taken from the secondary sources include:

  • Segmentations and percentage shares
  • Data for market value
  • Key industry trends of the top players in the market
  • Qualitative insights into various aspects of the market, key trends, and emerging areas of innovation
  • Quantitative data for mathematical and statistical calculations

Key Market Players and Competition Synopsis

Profiled companies have been selected based on primary insights, portfolio coverage, regulatory accreditations, and global biospecimen sourcing capabilities.

Established providers such as Crown Bioscience, Grifols S.A., BioIVT LLC, and Precision Medicine Group, LLC hold strong market positions with large, ethically sourced biospecimen inventories, CAP/ISO-certified biobanking operations, and long-standing partnerships with pharmaceutical, biotechnology, and diagnostics companies. Their expanding multi-omic-ready sample collections and data-rich offerings support advanced translational and precision-medicine research.

Emerging players, including Logical Biological and Labtoo, are gaining traction through flexible procurement models, disease-specific sample solutions, and digital sourcing platforms that simplify researchers' access to global biospecimens, especially within Europe and Asia-Pacific.

Together, these companies are strengthening global biospecimen supply chains, enhancing sample diversity, and improving traceability and regulatory compliance, driving the market toward higher-quality, clinically annotated resources that support drug discovery and diagnostic development.

Some prominent names established in this market are:

  • BioIVT LLC.
  • Crown Bioscience
  • Precision Medicine Group, LLC
  • Grifols, S.A.

Table of Contents

Executive Summary

Scope and Definition

1 Global Human Biospecimen Market: Industry Outlook

  • 1.1 Market Overview
    • 1.1.1 Market Overview and Market Trends
  • 1.2 Market Trends
    • 1.2.1 Impact Analysis
    • 1.2.2 Increasing Product Launches and Regulatory Approvals
    • 1.2.3 Increasing Collaboration between Players, Government Bodies, and Academia
  • 1.3 Supply Chain Overview
  • 1.4 Regulatory Landscape
    • 1.4.1 North America
      • 1.4.1.1 U.S.
      • 1.4.1.2 Canada
    • 1.4.2 Europe
      • 1.4.2.1 Germany
      • 1.4.2.2 U.K.
    • 1.4.3 Asia-Pacific
      • 1.4.3.1 China
      • 1.4.3.2 Japan
      • 1.4.3.3 Singapore
      • 1.4.3.4 Australia
      • 1.4.3.5 India
    • 1.4.4 Rest-of-the-World
      • 1.4.4.1 Latin America
      • 1.4.4.2 Africa
      • 1.4.4.3 Middle East and Other Emerging Regions
  • 1.5 Market Dynamics
    • 1.5.1 Drivers, Restraints, and Opportunities: Current and Future Impact Assessment
    • 1.5.2 Market Drivers
      • 1.5.2.1 Rising Adoption of Annotated Human Biospecimens
      • 1.5.2.2 Expansion of Biobanks and National Population Genomics Programs
      • 1.5.2.3 Surge in Cell and Gene Therapies, CAR-T, and Advanced Modalities
    • 1.5.3 Market Restraints
      • 1.5.3.1 Pre-Analytical Variability and Poor Biospecimen Quality
      • 1.5.3.2 Logistical, Storage, and Operational Challenges across the Biospecimen Lifecycle
    • 1.5.4 Market Opportunities
      • 1.5.4.1 Commercialization of Disease-Specific Rare-Disease Cohorts

2 Global Human Biospecimen Market, by Specimen Type

  • 2.1 Overview
  • 2.2 Tissue Specimens
    • 2.2.1 Formalin-Fixed Paraffin-Embedded (FFPE) Tissue
    • 2.2.2 Fresh Frozen Tissue
    • 2.2.3 Disease Tissue Sample
    • 2.2.4 Normal Tissue Sample
  • 2.3 Biofluids
    • 2.3.1 Whole Blood
    • 2.3.2 Plasma
    • 2.3.3 Serum
    • 2.3.4 Urine
    • 2.3.5 Saliva
    • 2.3.6 Cerebrospinal Fluid (CSF)
    • 2.3.7 Others
  • 2.4 Cellular Material
    • 2.4.1 Peripheral Blood Mononuclear Cells (PBMCs)
    • 2.4.2 Buccal Cells
    • 2.4.3 Stem Cells
    • 2.4.4 Primary Human Cells
    • 2.4.5 Purified Immune Cell Subsets
    • 2.4.6 Others
  • 2.5 Nucleic Acids
    • 2.5.1 Genomic DNA
    • 2.5.2 RNA
    • 2.5.3 ctDNA/cfDNA
  • 2.6 Others

3 Global Human Biospecimen Market (by Application)

  • 3.1 Overview
    • 3.1.1 Biomedical Research
    • 3.1.2 Diagnostics
    • 3.1.3 Therapeutic Development
    • 3.1.4 Clinical Trials

4 Global Human Biospecimen Market (by Procurement Type)

  • 4.1 Overview
    • 4.1.1 Prospective Collection (On-Demand Collection)
    • 4.1.2 Retrospective Samples

5 Global Human Biospecimen Market (by End User)

  • 5.1 Overview
    • 5.1.1 Pharmaceutical and Biotechnology Companies
    • 5.1.2 Contract Research Organizations (CROs)
    • 5.1.3 Academic and Research Institutes
    • 5.1.4 Hospitals and Biobanks
    • 5.1.5 Diagnostic Laboratories
    • 5.1.6 Government and Non-Profit Organizations

6 Region

  • 6.1 Regional Summary
  • 6.2 North America
    • 6.2.1 Regional Overview
    • 6.2.2 Driving Factors for Market Growth
    • 6.2.3 Factors Challenging the Market
    • 6.2.4 Market Sizing and Forecast
    • 6.2.5 U.S.
      • 6.2.5.1 Country Overview
      • 6.2.5.2 Market Sizing and Forecast
    • 6.2.6 Canada
      • 6.2.6.1 Country Overview
      • 6.2.6.2 Market Sizing and Forecast
  • 6.3 Europe
    • 6.3.1 Regional Overview
    • 6.3.2 Driving Factors for Market Growth
    • 6.3.3 Factors Challenging the Market
    • 6.3.4 Market Sizing and Forecast
    • 6.3.5 U.K.
      • 6.3.5.1 Country Overview
      • 6.3.5.2 Market Sizing and Forecast
    • 6.3.6 Germany
      • 6.3.6.1 Country Overview
      • 6.3.6.2 Market Sizing and Forecast
    • 6.3.7 France
      • 6.3.7.1 Country Overview
      • 6.3.7.2 Market Sizing and Forecast
    • 6.3.8 Italy
      • 6.3.8.1 Country Overview
      • 6.3.8.2 Market Sizing and Forecast
    • 6.3.9 Spain
      • 6.3.9.1 Country Overview
      • 6.3.9.2 Market Sizing and Forecast
    • 6.3.10 Rest-of-the- Europe
      • 6.3.10.1 Country Overview
      • 6.3.10.2 Market Sizing and Forecast
  • 6.4 Asia Pacific
    • 6.4.1 Regional Overview
    • 6.4.2 Driving Factors for Market Growth
    • 6.4.3 Factors Challenging the Market
    • 6.4.4 Market Sizing and Forecast
    • 6.4.5 China
      • 6.4.5.1 Country Overview
      • 6.4.5.2 Market Sizing and Forecast
    • 6.4.6 Japan
      • 6.4.6.1 Country Overview
      • 6.4.6.2 Market Sizing and Forecast
    • 6.4.7 India
      • 6.4.7.1 Country Overview
      • 6.4.7.2 Market Sizing and Forecast
    • 6.4.8 Australia
      • 6.4.8.1 Country Overview
      • 6.4.8.2 Market Sizing and Forecast
    • 6.4.9 South Korea
      • 6.4.9.1 Country Overview
      • 6.4.9.2 Market Sizing and Forecast
    • 6.4.10 Rest-of-the-Asia Pacific
      • 6.4.10.1 Country Overview
      • 6.4.10.2 Market Sizing and Forecast
  • 6.5 Rest-of-the-World
    • 6.5.1 Regional Overview
    • 6.5.2 Driving Factors for Market Growth
    • 6.5.3 Factors Challenging the Market
    • 6.5.4 Market Sizing and Forecast

7 Competitive Benchmarking and Company Profiles

  • 7.1 Key Strategies and Developments, 2020-2025
  • 7.2 Key Developments Analysis (by Year), 2020-2025
  • 7.3 Key Developments Analysis (by Company), 2020-2025
  • 7.4 Company Profiles
    • 7.4.1 BioIVT LLC.
      • 7.4.1.1 Overview
    • 7.4.2 Crown Bioscience
      • 7.4.2.1 Overview
    • 7.4.3 iProcess Global Research Inc.
      • 7.4.3.1 Overview
    • 7.4.4 ABS Bio, Inc.
      • 7.4.4.1 Overview
    • 7.4.5 Precision Medicine Group, LLC
      • 7.4.5.1 Overview
    • 7.4.6 REPROCELL Inc.
      • 7.4.6.1 Overview
    • 7.4.7 LifeNet Health LifeSciences
      • 7.4.7.1 Overview
    • 7.4.8 Logical Biological
      • 7.4.8.1 Overview
    • 7.4.9 Europa Biosite
      • 7.4.9.1 Overview
    • 7.4.10 Discovery Life Sciences
      • 7.4.10.1 Overview
    • 7.4.11 Boca Biolistics, LLC
      • 7.4.11.1 Overview
    • 7.4.12 ProteoGenex
      • 7.4.12.1 Overview
    • 7.4.13 US Biolab Corporation, Inc.
      • 7.4.13.1 Overview
    • 7.4.14 Bay Biosciences
      • 7.4.14.1 Overview
    • 7.4.15 Grifols, S.A.
      • 7.4.15.1 Overview

8 Research Methodology

  • 8.1 Data Sources
    • 8.1.1 Primary Data Sources
    • 8.1.2 Secondary Data Sources
    • 8.1.3 Inclusion and Exclusion
    • 8.1.4 Data Triangulation
  • 8.2 Market Estimation and Forecast

List of Figures

  • Figure 1: Global Human Biospecimen Market (by Scenario), $Million, 2024, 2028, and 2035
  • Figure 2: Global Human Biospecimen Market, 2024 and 2035
  • Figure 3: Top Countries, Global Human Biospecimen Market, $Million, 2024
  • Figure 4: Global Human Biospecimen Market Snapshot
  • Figure 5: Global Human Biospecimen Market, $Million, 2024 and 2035
  • Figure 6: Human Biospecimen Market (by Specimen Type), $Million, 2024, 2028, and 2035
  • Figure 7: Human Biospecimen Market (by Application), $Million, 2024, 2028, and 2035
  • Figure 8: Human Biospecimen Market (by Procurement Type), $Million, 2024, 2028, and 2035
  • Figure 9: Human Biospecimen Market (by End User), $Million, 2024, 2028, and 2035
  • Figure 10: Human Biospecimen Market Segmentation
  • Figure 11: Supply Chain Flow
  • Figure 12: Global Human Biospecimen Market (by Tissue Specimens), $Million, 2024, 2028, and 2035
  • Figure 13: Global Human Biospecimen Market (Formalin-Fixed Paraffin-Embedded (FFPE) Tissue), $Million, 2024-2035
  • Figure 14: Global Human Biospecimen Market (Fresh Frozen Tissue), $Million, 2024-2035
  • Figure 15: Global Human Biospecimen Market (Disease Tissue Sample), $Million, 2024-2035
  • Figure 16: Global Human Biospecimen Market (Normal Tissue Sample), $Million, 2024-2035
  • Figure 17: Global Human Biospecimen Market (by Biofluids), $Million, 2024, 2028, and 2035
  • Figure 18: Global Human Biospecimen Market (Whole Blood), $Million, 2024-2035
  • Figure 19: Global Human Biospecimen Market (Plasma), $Million, 2024-2035
  • Figure 20: Global Human Biospecimen Market (Serum), $Million, 2024-2035
  • Figure 21: Global Human Biospecimen Market (Urine), $Million, 2024-2035
  • Figure 22: Global Human Biospecimen Market (Saliva), $Million, 2024-2035
  • Figure 23: Global Human Biospecimen Market (Cerebrospinal Fluid (CSF)), $Million, 2024-2035
  • Figure 24: Global Human Biospecimen Market (Others), $Million, 2024-2035
  • Figure 25: Global Human Biospecimen Market (by Cellular Material), $Million, 2024, 2028, and 2035
  • Figure 26: Global Human Biospecimen Market, PBMCs (Peripheral Blood Mononuclear Cells (PBMCs)), $Million, 2024-2035
  • Figure 27: Global Human Biospecimen Market (Buccal Cells), $Million, 2024-2035
  • Figure 28: Global Human Biospecimen Market (Stem Cells), $Million, 2024-2035
  • Figure 29: Global Human Biospecimen Market (Primary Human Cells), $Million, 2024-2035
  • Figure 30: Global Human Biospecimen Market (Purified Immune Cell Subsets), $Million, 2024-2035
  • Figure 31: Global Human Biospecimen Market (Others), $Million, 2024-2035
  • Figure 32: Global Human Biospecimen Market (by Nucleic Acids), $Million, 2024, 2028, and 2035
  • Figure 33: Global Human Biospecimen Market (Genomic DNA), $Million, 2024-2035
  • Figure 34: Global Human Biospecimen Market (RNA), $Million, 2024-2035
  • Figure 35: Global Human Biospecimen Market (ctDNA/cfDNA), $Million, 2024-2035
  • Figure 36: Global Human Biospecimen Market (Others), $Million, 2024-2035
  • Figure 37: Global Human Biospecimen Market (by Application Type), $Million, 2024, 2028, and 2035
  • Figure 38: Global Human Biospecimen Market (Biomedical Research), $Million, 2024-2035
  • Figure 39: Global Human Biospecimen Market (Diagnostics), $Million, 2024-2035
  • Figure 40: Global Human Biospecimen Market (Therapeutic Development), $Million, 2024-2035
  • Figure 41: Global Human Biospecimen Market (Clinical Trials), $Million, 2024-2035
  • Figure 42: Global Human Biospecimen Market (by Procurement Type), $Million, 2024, 2028, and 2035
  • Figure 43: Global Human Biospecimen Market (Prospective Collection (On-Demand Collection)), $Million, 2024-2035
  • Figure 44: Global Human Biospecimen Market (Retrospective Samples), $Million, 2024-2035
  • Figure 45: Global Human Biospecimen Market (by End User), $Million, 2024, 2028, and 2035
  • Figure 46: Global Human Biospecimen Market (Pharmaceutical and Biotechnology Companies), $Million, 2024-2035
  • Figure 47: Global Human Biospecimen Market (Contract Research Organizations (CROs)), $Million, 2024-2035
  • Figure 48: Global Human Biospecimen Market (Academic and Research Institutes), $Million, 2024-2035
  • Figure 49: Global Human Biospecimen Market (Hospitals and Biobanks), $Million, 2024-2035
  • Figure 50: Global Human Biospecimen Market (Diagnostic Laboratories), $Million, 2024-2035
  • Figure 51: Global Human Biospecimen Market (Government and Non-Profit Organizations), $Million, 2024-2035
  • Figure 52: North America Human Biospecimen Market, $Million, 2024-2035
  • Figure 53: U.S. Human Biospecimen Market, $Million, 2024-2035
  • Figure 54: Canada Human Biospecimen Market, $Million, 2024-2035
  • Figure 55: Europe Human Biospecimen Market, $Million, 2024-2035
  • Figure 56: U.K. Human Biospecimen Market, $Million, 2024-2035
  • Figure 57: Germany Human Biospecimen Market, $Million, 2024-2035
  • Figure 58: France Human Biospecimen Market, $Million, 2024-2035
  • Figure 59: Italy Human Biospecimen Market, $Million, 2024-2035
  • Figure 60: Spain Human Biospecimen Market, $Million, 2024-2035
  • Figure 61: Rest-of-Europe Human Biospecimen Market, $Million, 2024-2035
  • Figure 62: Asia-Pacific Human Biospecimen Market, $Million, 2024-2035
  • Figure 63: China Human Biospecimen Market, $Million, 2024-2035
  • Figure 64: Japan Human Biospecimen Market, $Million, 2024-2035
  • Figure 65: India Human Biospecimen Market, $Million, 2024-2035
  • Figure 66: Australia Human Biospecimen Market, $Million, 2024-2035
  • Figure 67: South Korea Human Biospecimen Market, $Million, 2024-2035
  • Figure 68: Rest-of-Asia-Pacific Human Biospecimen Market, $Million, 2024-2035
  • Figure 69: Rest-of-the-World Human Biospecimen Market, $Million, 2024-2035
  • Figure 70: Key Strategies and Developments, 2020-2025
  • Figure 71: Key Strategies and Developments, 2020-2025
  • Figure 72: Inclusion and Exclusion Criteria for the Global Human Biospecimen Market
  • Figure 73: Data Triangulation
  • Figure 74: Top-Down and Bottom-Up Approach
  • Figure 75: Assumptions and Limitations

List of Tables

  • Table 1: Market Snapshot
  • Table 2: Key Market Trends
  • Table 3: Product Launches and Regulatory Approvals in the Human Biospecimen Market
  • Table 4: Collaborations in the Human Biospecimen Market
  • Table 5: Global Human Biospecimen Market (by Region), $Million, 2024-2035
  • Table 6: Global Human Biospecimen Market (by Region), $Million, 2024-2035
  • Table 7: Key Strategies and Developments, 2020-2025